Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.8B | $0.8B | $0.9B | $0.8B | 29.6% | 30.9% |
| 2025-12-31 | $2.9B | $0.8B | $0.9B | $0.7B | 27.7% | 30.2% |
| 2025-09-30 | $2.5B | $0.7B | $0.8B | $0.7B | 28.1% | 30.3% |
| 2025-06-30 | $2.4B | $0.7B | $0.7B | $0.6B | 27.0% | 30.5% |
| 2025-03-31 | $2.3B | $0.7B | $0.6B | $0.5B | 31.0% | 25.7% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-21 | 2.28 | 1.93 | +18.0% |
| 2026-01-22 | 2.21 | 1.95 | +13.3% |
| 2025-10-21 | 1.95 | 1.70 | +14.7% |
| 2025-07-22 | 1.81 | 1.61 | +12.4% |
| 2025-04-22 | 1.81 | 1.73 | +4.4% |
| 2025-01-23 | 2.21 | 1.79 | +23.7% |
| 2024-10-17 | 1.84 | 1.64 | +12.2% |
| 2024-07-18 | 1.78 | 1.54 | +15.5% |
| 2024-04-18 | 1.50 | 1.42 | +6.0% |
| 2024-01-23 | 1.60 | 1.49 | +7.7% |
| 2023-10-19 | 1.46 | 1.42 | +3.2% |
| 2023-07-20 | 1.42 | 1.33 | +6.9% |
| 2023-04-18 | 1.23 | 1.20 | +2.8% |
| 2023-01-24 | 1.23 | 1.25 | -1.9% |
| 2022-10-18 | 1.19 | 1.12 | +6.4% |
| 2022-07-21 | 1.14 | 1.20 | -4.8% |
| 2022-04-21 | 1.13 | 1.08 | +5.1% |
| 2022-01-20 | 1.30 | 1.28 | +1.6% |
| 2021-10-19 | 1.19 | 1.16 | +2.7% |
| 2021-07-20 | 1.31 | 1.02 | +28.1% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ISRG ★ | $142B | 48.6 | 34.0 | 13.4 | 35.5 | 8.1 | 66.3% | 23.0% | 18.8% | 1.59% |
| LLY | $965B | 38.4 | 24.3 | 13.4 | 27.3 | 31.0 | 82.8% | 55.5% | 169.9% | 0.95% |
| UNH | $350B | 29.0 | 18.5 | 0.8 | 18.5 | 3.6 | 18.8% | 2.0% | 0.7% | 5.06% |
| JNJ | $538B | 25.9 | 17.6 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $287B | 32.7 | 12.1 | 4.4 | 11.2 | 6.3 | 76.7% | 4.9% | — | 4.90% |
| ABBV | $385B | 106.4 | 13.4 | 6.1 | 14.8 | -57.9 | 72.0% | 12.4% | -46.2% | 5.40% |
| PFE | $145B | 19.4 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.55% |
| TMO | $176B | 26.1 | 17.4 | 3.9 | 19.4 | 3.3 | 40.9% | 6.2% | 11.3% | 3.14% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 34.28%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 30,075,905 | 8.49% |
| Vanguard Capital Management LLC | 23,079,490 | 6.52% |
| State Street Corporation | 15,846,973 | 4.47% |
| Price (T.Rowe) Associates Inc | 12,520,007 | 3.54% |
| Geode Capital Management, LLC | 8,466,851 | 2.39% |
| Capital World Investors | 8,048,010 | 2.27% |
| Vanguard Portfolio Management LLC | 7,233,971 | 2.04% |
| Morgan Stanley | 6,058,840 | 1.71% |
| FMR, LLC | 5,477,234 | 1.55% |
| JPMORGAN CHASE & CO | 4,593,894 | 1.30% |
Insider activity · 90d
No insider trades for ISRG in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 1.9375). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-02 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-05-28 | 8-K | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-20 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-11 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 4 | 2026-05-01 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-29 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-04-22 | 10-Q | view · |
| 8-K | 2026-04-21 | 8-K | view · |
| DEF 14A | 2026-03-13 | DEF 14A | view · |
| 4 | 2026-03-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-03-02 | 8-K | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 10-K | 2026-02-03 | 10-K | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-30 | PRIMARY DOCUMENT | view · |
About
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 a…